Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Adenosine and Cilostazol

supplement:

Adenosine

Research Papers that Mention the Interaction

Recent preclinical studies have demonstrated that CLZ also possesses the ability to inhibit adenosine uptake by various cells, a property that distinguishes CLZ from other PDE3 inhibitors, such as milrinone.
Current pharmaceutical design  •  2003  |  View Paper
In the present studies, cilostazol inhibited [3H]-adenosine uptake in both platelets and erythrocytes with a … 7 &mgr;M. Next collagen-induced platelet aggregation was studied and it was found that adenosine (1 &mgr;M), having … the IC50 of cilostazol from 2.66 &mgr;M …;M (p < 0.01).
Journal of cardiovascular pharmacology  •  2002  |  View Paper
These data show that cilostazol , unlike milrinone, inhibits adenosine uptake, and thus potentiates adenosine accumulation from a 2-min ischemia.
Journal of cardiovascular pharmacology  •  2000  |  View Paper
Cilostazol inhibits PDE III in platelets through an increase in adenosine 3 ́,5 ́-cyclic monophosphate (cAMP) content and activation of protein kinase A, resulting in antiplatelet aggregation.
Journal of atherosclerosis and thrombosis  •  2016  |  View Paper
Adding a low concentration of adenosine (0.3 microM) did not inhibit shear-induced platelet aggregation, but significantly enhanced the inhibitory effect of cilostazol in platelet-rich plasma.
Thrombosis research  •  2007  |  View Paper
Cilostazol is classified as an antiplatelet agent because it inhibits the platelet aggregation induced by collagen, 5'-adenosine diphosphate ( ADP ), epinephrine, and arachidonic acid.
Atherosclerosis. Supplements  •  2005  |  View Paper
Papaverine, cilostazol , and rolipram also augmented both the magnitude and the duration of Isc following low dose stimulation of adenosine receptors with Ado (0.1-1.0 microM, P < 0.01).
American journal of respiratory cell and molecular biology  •  2003  |  View Paper
Cilostazol is a phosphodiesterase III inhibitor increases adenosine 3' , 5'-cyclic monophosphate (cyclic AMP) level which inhibits hepatic stellate cell activation.
European journal of pharmacology  •  2015  |  View Paper
Cilostazol and draflazine increased the dialysate adenosine concentration during the first 10 min of muscle contraction, but had no effect during ischemia, most likely because of the high AMP deaminase activity in skeletal muscle.
Circulation journal : official journal of the Japanese Circulation Society  •  2010  |  View Paper
In the cerebral arterioles, low concentration (10–6M) of cilostazol or milrinone caused a significant shift of the dose-vasodilatory response curve for adenosine to the left.
Journal of Vascular Research  •  2005  |  View Paper
Show More